KOD - Kodiak cut to Neutral at UBS as lead asset dropped from trials
2023-07-27 14:33:09 ET
More on Kodiak Sciences
- Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape
- Kodiak gains as late-stage trial for eye disease candidate meets key goal
- Kodiak cut to Sell at Citi on potential setback to lead asset in August
- Seeking Alpha’s Quant Rating on Kodiak Sciences
- Earnings data for Kodiak Sciences
For further details see:
Kodiak cut to Neutral at UBS as lead asset dropped from trials